Ablynx NV (ABLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Nov-2017

No. of Pages : 78

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ablynx NV, Medical Devices Deals, 2011 to YTD 2017 10
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 13
Partnerships 14
Ablynx Enters into Research Agreement with Genzyme 14
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 15
Taiwan Liposome and Ablynx Enter into Research Agreement 16
Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 17
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 18
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 19
Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 20
Licensing Agreements 21
Sanofi Enters into Licensing Agreement with Ablynx 21
Novo Nordisk Enters into Licensing Agreement with Ablynx 22
Taisho Pharma Enters into Licensing Agreement with Ablynx 23
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 24
Merck Expands Licensing Agreement with Ablynx 25
Ablynx Enters Into Licensing Agreement With Eddingpharm 27
Equity Offering 29
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 29
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 31
Ablynx Amends Private Placement of Shares 32
Ablynx Raises USD1.05 Million Through Exercise of Warrants 34
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 35
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 36
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD82.6 Million in Private Placement of Shares 38
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 40
Ablynx Raises USD1.4 Million upon Exercise of Warrants 41
Ablynx Raises USD57 Million in Private Placement of Shares 42
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Ablynx Completes Private Placement Of Shares For US$41 Million 45
Debt Offering 46
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 46
Acquisition 47
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 47
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 48
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 49
Ablynx NV - Key Competitors 50
Ablynx NV - Key Employees 51
Ablynx NV - Locations And Subsidiaries 52
Head Office 52
Recent Developments 53
Financial Announcements 53
Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 53
Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 55
May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 58
Feb 23, 2017: Ablynx Announces 2016 Full Year Results 60
Nov 23, 2016: Ablynx Announces Results For The First Nine Months Of 2016 And A Year-To-Date Business Update 61
Aug 25, 2016: Ablynx Announces 2016 Half-year Results And Year-to-date Business Update 63
May 12, 2016: Ablynx Reports Financial Results For The First Three Months Of 2016 And Provides Business Update Year-To-Date 67
Feb 25, 2016: Ablynx Announces 2015 Full Year Results 69
Corporate Communications 71
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 71
Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 72
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 73
Clinical Trials 74
Jan 11, 2017: Ablynx Initiates Phase IIb "Respire" Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 74
May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association 76
Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ablynx NV, Deals By Therapy Area, 2011 to YTD 2017 9
Ablynx NV, Medical Devices Deals, 2011 to YTD 2017 10
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 13
Ablynx Enters into Research Agreement with Genzyme 14
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 15
Taiwan Liposome and Ablynx Enter into Research Agreement 16
Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 17
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 18
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics 19
Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 20
Sanofi Enters into Licensing Agreement with Ablynx 21
Novo Nordisk Enters into Licensing Agreement with Ablynx 22
Taisho Pharma Enters into Licensing Agreement with Ablynx 23
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 24
Merck Expands Licensing Agreement with Ablynx 25
Ablynx Enters Into Licensing Agreement With Eddingpharm 27
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 29
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 31
Ablynx Amends Private Placement of Shares 32
Ablynx Raises USD1.05 Million Through Exercise of Warrants 34
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 35
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 36
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD82.6 Million in Private Placement of Shares 38
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 40
Ablynx Raises USD1.4 Million upon Exercise of Warrants 41
Ablynx Raises USD57 Million in Private Placement of Shares 42
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Ablynx Completes Private Placement Of Shares For US$41 Million 45
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 46
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 47
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 48
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 49
Ablynx NV, Key Competitors 50
Ablynx NV, Key Employees 51

List of Figures
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ablynx NV, Medical Devices Deals, 2011 to YTD 2017 10

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Ablynx NV (ABLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027